BIA
CLDX icon

Barry Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

Barry Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-667
Closed -$2K – 74
2018
Q4 		$2K Hold
667
– – ﹤0.01% 73
2018
Q3 		$5K Hold
667
– – ﹤0.01% 74
2018
Q2 		$5K Hold
667
– – ﹤0.01% 71
2018
Q1 		$23K Hold
667
– – 0.01% 69
2017
Q4 		$28K Hold
667
– – 0.01% 70
2017
Q3 		$29K Hold
667
– – 0.01% 69
2017
Q2 		$25K Hold
667
– – 0.01% 66
2017
Q1 		$36K Sell
667
-600
-47% -$31.2K 0.01% 71
2016
Q4 		$67K Hold
1,267
– – 0.02% 70
2016
Q3 		$77K Buy
+1,267
New +$78.9K 0.03% 71

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Barry Investment Advisors's CLDX Position: Q1 2019 in Review

Barry Investment Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 667 shares — an estimated $2K sold.

Barry Investment Advisors first reported a position in CLDX in Q3 2016 and held it in 10 quarters. The position peaked at $77K in Q3 2016. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Barry Investment Advisors reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Barry Investment Advisors sold 667 Celldex Therapeutics shares in Q1 2019, an estimated $2K.
  • Barry Investment Advisors first reported a position in Celldex Therapeutics in Q3 2016 and held it in 10 quarters.
  • Barry Investment Advisors's Celldex Therapeutics position peaked at $77K in Q3 2016.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Barry Investment Advisors's 13F filing for Q1 2019, filed 26 Apr 2019.